Rosalind Advisors Inc. Has $1.61 Million Position in ABIVAX Société Anonyme (NASDAQ:ABVX)

Rosalind Advisors Inc. cut its stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 63.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 139,983 shares of the company's stock after selling 238,433 shares during the quarter. ABIVAX Société Anonyme makes up approximately 1.0% of Rosalind Advisors Inc.'s investment portfolio, making the stock its 20th largest position. Rosalind Advisors Inc. owned approximately 0.22% of ABIVAX Société Anonyme worth $1,613,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of ABIVAX Société Anonyme during the 1st quarter worth $81,000. Kennedy Capital Management LLC increased its position in ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock worth $1,718,000 after buying an additional 31,331 shares during the period. Janus Henderson Group PLC raised its holdings in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock valued at $12,113,000 after buying an additional 131,414 shares during the last quarter. Finally, abrdn plc lifted its holdings in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. Hedge funds and other institutional investors own 47.91% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Laidlaw assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, July 29th. They set a "buy" rating and a $48.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $36.50.

ABIVAX Société Anonyme Stock Up 1.5 %

Shares of NASDAQ ABVX traded up $0.15 during midday trading on Wednesday, reaching $10.40. The company's stock had a trading volume of 18,877 shares, compared to its average volume of 92,457. ABIVAX Société Anonyme has a one year low of $8.75 and a one year high of $17.02. The company has a 50 day moving average price of $10.94 and a 200 day moving average price of $12.40.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.